Condition
Graft Versus Host Disease (GVHD)
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Terminated2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04167514Phase 3CompletedPrimary
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
NCT01324908Not ApplicableTerminatedPrimary
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis
NCT02167451Phase 1Terminated
Maraviroc as GVHD Prophylaxis in Transplant Recipients
NCT01463475Not ApplicableCompletedPrimary
University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol
Showing all 4 trials